Florentino Sánchez-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Florentino Sánchez-García has a total of 341 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Blanco
Department of Allergy Hospital Universitario de La Princesa, IIS‐Princesa Madrid Spain
6 shared publications Teresa Carrillo
Allergy Unit, Hospital Universitario Dr Negrín, Gran Canaria, Spain
5 shared publications- Joaquín Quiralte
Allergy Department, Vírgen del Rocío University Hospital, Seville, Spain
3 shared publications Nancy Ortega
3 shared publicationsRodolfo Castillo
3 shared publications- Benedetta Nacmias
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
2 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (5) , 1201-1203
HLA-DRB1*15:01 allele protects from asthma susceptibility
- 1 November 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (5) , 1201-1203
HLA-DRB1*15:01 allele protects from asthma susceptibility
- Top Cited Papers
- 27 October 2013
- Published by Springer Nature in Nature Genetics
- Vol. 45 (12) , 1452-1458
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
Philippe Amouyel, Julie Williams, Gerard Schellenberg, Sudha Seshadri and colleagues report a meta-analysis of genome-wide association studies for late-onset Alzheimer's disease in 17,008 cases and 37,154 controls with replication in an additional 8,572 cases and 11,312 controls. They identify 11 loci newly associated with Alzheimer's disease. Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10−8) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.
- 27 October 2013
- Published by Springer Nature in Nature Genetics
- Vol. 45 (12) , 1452-1458
Top Cited PapersMeta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
Philippe Amouyel, Julie Williams, Gerard Schellenberg, Sudha Seshadri and colleagues report a meta-analysis of genome-wide association studies for late-onset Alzheimer's disease in 17,008 cases and 37,154 controls with replication in an additional 8,572 cases and 11,312 controls. They identify 11 loci newly associated with Alzheimer's disease. Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10−8) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.
- Open Access
- 20 March 2012
- Published by Springer Nature in Molecular Psychiatry
- Vol. 18 (4) , 461-470
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease
Recently, several genome-wide association studies (GWASs) have led to the discovery of nine new loci of genetic susceptibility in Alzheimer's disease (AD). However, the landscape of the AD genetic susceptibility is far away to be complete and in addition to single-SNP (single-nucleotide polymorphism) analyses as performed in conventional GWAS, complementary strategies need to be applied to overcome limitations inherent to this type of approaches. We performed a genome-wide haplotype association (GWHA) study in the EADI1 study (n=2025 AD cases and 5328 controls) by applying a sliding-windows approach. After exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with suggestive haplotype effects were identified. In a second step, we attempted to replicate the best suggestive haplotype associations in the GERAD1 consortium (2820 AD cases and 6356 controls) and observed that 9 of them showed nominal association. In a third step, we tested relevant haplotype associations in a combined analysis of five additional case–control studies (5093 AD cases and 4061 controls). We consistently replicated the association of a haplotype within FRMD4A on Chr.10p13 in all the data set analyzed (OR: 1.68; 95% CI: (1.43–1.96); P=1.1 × 10−10). We finally searched for association between SNPs within the FRMD4A locus and Aβ plasma concentrations in three independent non-demented populations (n=2579). We reported that polymorphisms were associated with plasma Aβ42/Aβ40 ratio (best signal, P=5.4 × 10−7). In conclusion, combining both GWHA study and a conservative three-stage replication approach, we characterised FRMD4A as a new genetic risk factor of AD.
- 20 March 2012
- Published by Springer Nature in Molecular Psychiatry
- Vol. 18 (4) , 461-470
Open AccessGenome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease
Recently, several genome-wide association studies (GWASs) have led to the discovery of nine new loci of genetic susceptibility in Alzheimer's disease (AD). However, the landscape of the AD genetic susceptibility is far away to be complete and in addition to single-SNP (single-nucleotide polymorphism) analyses as performed in conventional GWAS, complementary strategies need to be applied to overcome limitations inherent to this type of approaches. We performed a genome-wide haplotype association (GWHA) study in the EADI1 study (n=2025 AD cases and 5328 controls) by applying a sliding-windows approach. After exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with suggestive haplotype effects were identified. In a second step, we attempted to replicate the best suggestive haplotype associations in the GERAD1 consortium (2820 AD cases and 6356 controls) and observed that 9 of them showed nominal association. In a third step, we tested relevant haplotype associations in a combined analysis of five additional case–control studies (5093 AD cases and 4061 controls). We consistently replicated the association of a haplotype within FRMD4A on Chr.10p13 in all the data set analyzed (OR: 1.68; 95% CI: (1.43–1.96); P=1.1 × 10−10). We finally searched for association between SNPs within the FRMD4A locus and Aβ plasma concentrations in three independent non-demented populations (n=2579). We reported that polymorphisms were associated with plasma Aβ42/Aβ40 ratio (best signal, P=5.4 × 10−7). In conclusion, combining both GWHA study and a conservative three-stage replication approach, we characterised FRMD4A as a new genetic risk factor of AD.
- 5 September 2008
- Published by Wiley in European Journal of Neurology
- Vol. 15 (10) , 1080-1084
Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain
Aims: Previous studies have reported the presence of low‐grade inflammation in Alzheimer disease (AD). Based on these data, our work attempts to investigate the effects of some promoter polymorphisms of pro‐inflammatory cytokines [interleukin (IL)‐1 alpha and IL‐1 beta] on AD.Patients and methods: A PCR‐RFLP technique was used to analyze the promoter polymorphisms of both IL‐1 alpha (−889 C/T) and IL‐1 beta (−511 C/T) and the APOE genotype from the DNA samples of 282 patients (according to NINCDS‐ADRDA criteria) and 312 control subjects.Results: (i) The risk of developing AD in our population was associated with the IL‐1 beta (−511 C/T) promoter polymorphism; (ii) such risk was independent of the risk factor allele in the APOE gene (APOE4); and (iii) the IL‐1 alpha promoter polymorphism (−889 C/T) was not associated with the disease.Conclusion: In our population, IL‐1 beta promoter polymorphism (−511 C/T) is an independent risk factor for AD.
- 5 September 2008
- Published by Wiley in European Journal of Neurology
- Vol. 15 (10) , 1080-1084
Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain
Aims: Previous studies have reported the presence of low‐grade inflammation in Alzheimer disease (AD). Based on these data, our work attempts to investigate the effects of some promoter polymorphisms of pro‐inflammatory cytokines [interleukin (IL)‐1 alpha and IL‐1 beta] on AD.Patients and methods: A PCR‐RFLP technique was used to analyze the promoter polymorphisms of both IL‐1 alpha (−889 C/T) and IL‐1 beta (−511 C/T) and the APOE genotype from the DNA samples of 282 patients (according to NINCDS‐ADRDA criteria) and 312 control subjects.Results: (i) The risk of developing AD in our population was associated with the IL‐1 beta (−511 C/T) promoter polymorphism; (ii) such risk was independent of the risk factor allele in the APOE gene (APOE4); and (iii) the IL‐1 alpha promoter polymorphism (−889 C/T) was not associated with the disease.Conclusion: In our population, IL‐1 beta promoter polymorphism (−511 C/T) is an independent risk factor for AD.
- 29 October 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 427 (1) , 34-38
Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain)
- 29 October 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 427 (1) , 34-38
Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain)
- Open Access
- 10 September 2007
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 9 (5) , R89
Association of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study
CD40–CD154 interaction is an important mediator of inflammation and has been implicated in T helper type 1-mediated autoimmune diseases including rheumatoid arthritis (RA). Linkage studies have shown association of markers in the proximity of the CD154 gene. In the present work we investigated whether specific allele variants of the microsatellite in the 3' UTR of the CD154 gene might modulate the risk of RA. The study, in a case-control setting, included 189 patients and 150 healthy controls from the Canary Islands, Spain. The 24CAs allele was less represented in female patients than in controls (0.444 in controls versus 0.307 in patients, P = 0.006, odds ratio (OR) 0.556, 95% confidence interval (CI) 0.372 to 0.831) but not in males (0.414 versus 0.408), and only when homozygous (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77). We also verified that CD154 association with RA was independent of human leukocyte antigen (HLA) phenotype. A further functional study showed that after stimulation anti-CD3, CD154 mRNA was more stable in CD4+ T lymphocytes from patients with RA bearing the 24CAs allele (mRNA half-life 208 minutes) than in patients without the 24CAs allele (109 minutes, P = 0.009). However, a lower percentage of CD154+CD4+ T lymphocytes was seen in freshly isolated peripheral blood mononuclear cells from patients carrying 24CAs alleles (mean 4.28 versus 8.12; P = 0.033), and also in CD4+ T lymphocytes stimulated with anti-CD3 (median 29.40 versus 47.60; P = 0.025). These results were concordant with the smaller amounts of CD154 mRNA isolated from stimulated T lymphocytes with 24CAs alleles. The CD154 microsatellite therefore seems to affect the expression of the gene in a complex manner that implies not only mRNA stability. These data suggest that the CD154 microsatellite contributes to the regulation of mRNA and protein expression, although further studies will be necessary to elucidate its role in disease predisposition.
- 10 September 2007
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 9 (5) , R89
Open AccessAssociation of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study
CD40–CD154 interaction is an important mediator of inflammation and has been implicated in T helper type 1-mediated autoimmune diseases including rheumatoid arthritis (RA). Linkage studies have shown association of markers in the proximity of the CD154 gene. In the present work we investigated whether specific allele variants of the microsatellite in the 3' UTR of the CD154 gene might modulate the risk of RA. The study, in a case-control setting, included 189 patients and 150 healthy controls from the Canary Islands, Spain. The 24CAs allele was less represented in female patients than in controls (0.444 in controls versus 0.307 in patients, P = 0.006, odds ratio (OR) 0.556, 95% confidence interval (CI) 0.372 to 0.831) but not in males (0.414 versus 0.408), and only when homozygous (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77). We also verified that CD154 association with RA was independent of human leukocyte antigen (HLA) phenotype. A further functional study showed that after stimulation anti-CD3, CD154 mRNA was more stable in CD4+ T lymphocytes from patients with RA bearing the 24CAs allele (mRNA half-life 208 minutes) than in patients without the 24CAs allele (109 minutes, P = 0.009). However, a lower percentage of CD154+CD4+ T lymphocytes was seen in freshly isolated peripheral blood mononuclear cells from patients carrying 24CAs alleles (mean 4.28 versus 8.12; P = 0.033), and also in CD4+ T lymphocytes stimulated with anti-CD3 (median 29.40 versus 47.60; P = 0.025). These results were concordant with the smaller amounts of CD154 mRNA isolated from stimulated T lymphocytes with 24CAs alleles. The CD154 microsatellite therefore seems to affect the expression of the gene in a complex manner that implies not only mRNA stability. These data suggest that the CD154 microsatellite contributes to the regulation of mRNA and protein expression, although further studies will be necessary to elucidate its role in disease predisposition.
- 30 June 2007
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 19 (3) , 136-142
Utilidad del índice aterogénico en la predicción de enfermedad coronaria prematura
- 30 June 2007
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 19 (3) , 136-142
Utilidad del índice aterogénico en la predicción de enfermedad coronaria prematura
- 15 June 2007
- Published by Wiley in Tissue Antigens
- Vol. 70 (3) , 258-259
HLA-A*68020103 shows an eight nucleotides deletion within intron 2 but has normal mRNA splicing and serological recognition
- 15 June 2007
- Published by Wiley in Tissue Antigens
- Vol. 70 (3) , 258-259
HLA-A*68020103 shows an eight nucleotides deletion within intron 2 but has normal mRNA splicing and serological recognition
- 2 December 2004
- Vol. 39 (10) , 911-4
[Familial multiple sclerosis in Canary Islands].
Multiple sclerosis (MS) is an autoimmune disease that occurs in genetically predisposed individuals. Its inheritance is polygenic. Genetic epidemiology studies have shown an increased familial aggregation. AIM. To determine the prevalence of familial MS (fMS) in a series of patients from the Canary Islands. From a cohort of 266 patients with defined MS, during a 6-year period, we investigated prospectively by personal interviews the presence of MS on first and second degree relatives. We analysed as well the presence of HLA DRB1 in affected families, and also clinical and demographic characteristics in fMS and compared them with sporadic MS (sMS). fMS prevalence was 13.9% (27 non-related families with 50 affected individuals). The HLA DRB01*1501 allele were present in 51,8% of familial cases. We could not found either intrafamilial concordance in clinically affected regions and age of onset or clinical evolution. We have not found any phenotypic differences between familial and sMS. The prevalence of fMS in our series is comparable to that in other Mediterranean populations. Our results do not support that fMS was a different clinical entity of sMS and intrafamilial concordance in its clinical expression.
- 2 December 2004
- Vol. 39 (10) , 911-4
[Familial multiple sclerosis in Canary Islands].
Multiple sclerosis (MS) is an autoimmune disease that occurs in genetically predisposed individuals. Its inheritance is polygenic. Genetic epidemiology studies have shown an increased familial aggregation. AIM. To determine the prevalence of familial MS (fMS) in a series of patients from the Canary Islands. From a cohort of 266 patients with defined MS, during a 6-year period, we investigated prospectively by personal interviews the presence of MS on first and second degree relatives. We analysed as well the presence of HLA DRB1 in affected families, and also clinical and demographic characteristics in fMS and compared them with sporadic MS (sMS). fMS prevalence was 13.9% (27 non-related families with 50 affected individuals). The HLA DRB01*1501 allele were present in 51,8% of familial cases. We could not found either intrafamilial concordance in clinically affected regions and age of onset or clinical evolution. We have not found any phenotypic differences between familial and sMS. The prevalence of fMS in our series is comparable to that in other Mediterranean populations. Our results do not support that fMS was a different clinical entity of sMS and intrafamilial concordance in its clinical expression.
- 1 November 2004
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 114 (5) , 1070-1076
Genetic basis of the latex-fruit syndrome: Association with HLA class II alleles in a Spanish population
- 1 November 2004
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 114 (5) , 1070-1076
Genetic basis of the latex-fruit syndrome: Association with HLA class II alleles in a Spanish population